Clinical practice guideline for Sjögren’s syndrome 2017

Takayuki Sumida; Naoto Azuma; Masafumi Moriyama; Hiroyuki Takahashi; Hiromitsu Asashima; Fumika Honda; Saori Abe; Yuko Ono; Tomoya Hirota; Shintaro Hirata; Yoshiya Tanaka; Toshimasa Shimizu; Hideki Nakamura; Atsushi Kawakami; Hajime Sano; Yoko Ogawa; Kazuo Tsubota; Koufuchi Ryo; Ichiro Saito; Akihiko Tanaka; Seiji Nakamura; Etsuko Takamura; Masao Tanaka; Katsuya Suzuki; Tsutomu Takeuchi; Noriyuki Yamakawa; Tsuneyo Mimori; Akiko Ohta; Susumu Nishiyama; Toshio Yoshihara; Yasunori Suzuki; Mitsuhiro Kawano; Minako Tomiita; Hiroto Tsuboi

doi:10.1080/14397595.2018.1438093

Clinical practice guideline for Sjögren’s syndrome 2017

Takayuki Sumida, Naoto Azuma, Masafumi Moriyama, Hiroyuki Takahashi, Hiromitsu Asashima, Fumika Honda, Saori Abe, Yuko Ono, Tomoya Hirota, Shintaro Hirata, Yoshiya Tanaka, Toshimasa Shimizu, Hideki Nakamura, Atsushi Kawakami, Hajime Sano, Yoko Ogawa, Kazuo Tsubota, Koufuchi Ryo, Ichiro Saito, Akihiko TanakaSeiji Nakamura, Etsuko Takamura, Masao Tanaka, Katsuya Suzuki, Tsutomu Takeuchi, Noriyuki Yamakawa, Tsuneyo Mimori, Akiko Ohta, Susumu Nishiyama, Toshio Yoshihara, Yasunori Suzuki, Mitsuhiro Kawano, Minako Tomiita, Hiroto Tsuboi

Research output: Contribution to journal › Review article › peer-review

38 Citations (Scopus)

Abstract

Objectives: The objective of this study is to develop clinical practice guideline (CPG) for Sjögren’s syndrome (SS) based on recently available clinical and therapeutic evidences. Methods: The CPG committee for SS was organized by the Research Team for Autoimmune Diseases, Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Japan. The committee completed a systematic review of evidences for several clinical questions and developed CPG for SS 2017 according to the procedure proposed by the Medical Information Network Distribution Service (Minds). The recommendations and their strength were checked by the modified Delphi method. The CPG for SS 2017 has been officially approved by both Japan College of Rheumatology and the Japanese Society for SS. Results: The CPG committee set 38 clinical questions for clinical symptoms, signs, treatment, and management of SS in pediatric, adult and pregnant patients, using the PICO (P: patients, problem, population, I: interventions, C: comparisons, controls, comparators, O: outcomes) format. A summary of evidence, development of recommendation, recommendation, and strength for these 38 clinical questions are presented in the CPG. Conclusion: The CPG for SS 2017 should contribute to improvement and standardization of diagnosis and treatment of SS.

Original language	English
Pages (from-to)	383-408
Number of pages	26
Journal	Modern rheumatology
Volume	28
Issue number	3
DOIs	https://doi.org/10.1080/14397595.2018.1438093
Publication status	Published - 2018 May 4

Keywords

Medical Information Network Distribution Service (Minds)
Sjögren’s syndrome
clinical practice guideline
clinical question
systematic review

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1080/14397595.2018.1438093

Cite this

Sumida, T., Azuma, N., Moriyama, M., Takahashi, H., Asashima, H., Honda, F., Abe, S., Ono, Y., Hirota, T., Hirata, S., Tanaka, Y., Shimizu, T., Nakamura, H., Kawakami, A., Sano, H., Ogawa, Y., Tsubota, K., Ryo, K., Saito, I., ... Tsuboi, H. (2018). Clinical practice guideline for Sjögren’s syndrome 2017. Modern rheumatology, 28(3), 383-408. https://doi.org/10.1080/14397595.2018.1438093

Sumida, T, Azuma, N, Moriyama, M, Takahashi, H, Asashima, H, Honda, F, Abe, S, Ono, Y, Hirota, T, Hirata, S, Tanaka, Y, Shimizu, T, Nakamura, H, Kawakami, A, Sano, H, Ogawa, Y, Tsubota, K, Ryo, K, Saito, I, Tanaka, A, Nakamura, S, Takamura, E, Tanaka, M, Suzuki, K, Takeuchi, T, Yamakawa, N, Mimori, T, Ohta, A, Nishiyama, S, Yoshihara, T, Suzuki, Y, Kawano, M, Tomiita, M & Tsuboi, H 2018, 'Clinical practice guideline for Sjögren’s syndrome 2017', Modern rheumatology, vol. 28, no. 3, pp. 383-408. https://doi.org/10.1080/14397595.2018.1438093

@article{5ee39bd32edf46eca193dfe36c57f33f,

title = "Clinical practice guideline for Sj{\"o}gren{\textquoteright}s syndrome 2017",

abstract = "Objectives: The objective of this study is to develop clinical practice guideline (CPG) for Sj{\"o}gren{\textquoteright}s syndrome (SS) based on recently available clinical and therapeutic evidences. Methods: The CPG committee for SS was organized by the Research Team for Autoimmune Diseases, Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Japan. The committee completed a systematic review of evidences for several clinical questions and developed CPG for SS 2017 according to the procedure proposed by the Medical Information Network Distribution Service (Minds). The recommendations and their strength were checked by the modified Delphi method. The CPG for SS 2017 has been officially approved by both Japan College of Rheumatology and the Japanese Society for SS. Results: The CPG committee set 38 clinical questions for clinical symptoms, signs, treatment, and management of SS in pediatric, adult and pregnant patients, using the PICO (P: patients, problem, population, I: interventions, C: comparisons, controls, comparators, O: outcomes) format. A summary of evidence, development of recommendation, recommendation, and strength for these 38 clinical questions are presented in the CPG. Conclusion: The CPG for SS 2017 should contribute to improvement and standardization of diagnosis and treatment of SS.",

keywords = "Medical Information Network Distribution Service (Minds), Sj{\"o}gren{\textquoteright}s syndrome, clinical practice guideline, clinical question, systematic review",

author = "Takayuki Sumida and Naoto Azuma and Masafumi Moriyama and Hiroyuki Takahashi and Hiromitsu Asashima and Fumika Honda and Saori Abe and Yuko Ono and Tomoya Hirota and Shintaro Hirata and Yoshiya Tanaka and Toshimasa Shimizu and Hideki Nakamura and Atsushi Kawakami and Hajime Sano and Yoko Ogawa and Kazuo Tsubota and Koufuchi Ryo and Ichiro Saito and Akihiko Tanaka and Seiji Nakamura and Etsuko Takamura and Masao Tanaka and Katsuya Suzuki and Tsutomu Takeuchi and Noriyuki Yamakawa and Tsuneyo Mimori and Akiko Ohta and Susumu Nishiyama and Toshio Yoshihara and Yasunori Suzuki and Mitsuhiro Kawano and Minako Tomiita and Hiroto Tsuboi",

note = "Funding Information: Therefore, standardization of diagnosis and treatment of SS is needed for appropriate management and accurate certification of designated intractable disease. CPG based on recently available evidences should also contribute to standardization of clinical practices across the country. The treatment guideline by the SS Foundation of the United States of America (USA) [2] and the management guideline for SS by the British Society for Rheumatology (BSR) [3] were published recently. Moreover, the CPG committee for SS, organized by the Research Team for Autoimmune Diseases, the Research Program for Intractable Disease of MHLW, has developed {\textquoteleft}CPG for SS 2017{\textquoteright} [4] which has been officially approved by both the Japan College of Rheumatology (JCR) and the Japanese society for SS (JSSS), according to the procedure proposed by the Medical Information Network Distribution Service (Minds) [5]. Funding Information: diseases are organized and supported by the Research Program for Intractable Disease of MHLW and the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED). The Research Program for Intractable Disease of MHLW provides support for epidemiological studies, establishes diagnostic and severity criteria, develops clinical practice guideline (CPG) based on clinical and therapeutic evidences, and distributes and revises these criteria and CPG. On the other hand, the Practical Research Project for Rare/ Intractable Diseases from AMED supports clinical research on gene therapy and clinical application of new therapies and medical devices, and provides financial support for physician-led clinical trials. Moreover, patients with designated intractable diseases can obtain medical expenses subsidy once they satisfy certain diagnostic and severity criteria. Funding Information: T. S. has received honoraria from Astellas, Chugai, and Mitsubishi Tanabe; research grants from Astellas, Bristol-Myers Squibb, Chugai, Mitsubishi Tanabe, and Ono. H. A. has received a research grant from Mitsubishi Tanabe. S. H. has received honoraria from AbbVie. Y. T. has received honoraria from AbbVie, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Teijin Pharma, Sanofi, Pfizer, Takeda, and Y. L. Biologics; research grants from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai., Eli Lilly, Kowa, Limited, Kyowa Hakko Kirin, Mitsubishi Tanabe, MSD, Novartis, Pfizer, Sanofi, Shionogi, Taisho Toyama, and Takeda. A. K. has received honoraria from AbbVie, Astellas, AstraZeneca, Bristol-Myers Squibb, Kissei, Mitsubishi Tanabe, Ono., Pfizer, and Takeda; research grants from Actelion, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Ono, and Takeda. H. S. has honorariums from Astellas, Bristol-Myers Squibb, Chugai, Mitsubishi Tanabe and Pfizer; research grants from Astellas and Chugai. K. T. has received research grants from Alcon, JINS, Santen, Fuji Xerox, Kowa, Ophtecs, Otsuka, QD Laser, Rohto, Sucampo Pharma, Pfizer, Tsubota Laboratory and Wakasa Seikatsu. M. T. has received research grants from AbbVie and Astellas; has belonged to the Donated Fund Laboratory sponsored by Mitsubishi Tanabe, Chugai, Bristol-Myers Squibb and Eisai. K. S. has received honoraria from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Fuji Film, Janssen, Kissei, Mitsubishi Tanabe, Pfizer, Shionogi and Takeda; research grants from Bristol-Myers Squibb, Daiichi Sankyo, Eisai and Kissei; consulting fees from AbbVie and Pfizer. T. T. has received honoraria from AbbVie, Astellas, Chugai, Daiichi Sankyo, Mitsubishi Tanabe and Pfizer; received research grants from AbbVie, Asahikasei Pharma, Astellas, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Nipponkayaku, Pfizer, Taisyo Toyama, Takeda, and Teijin Pharma; consulting fees from AbbVie, Astellas, Astra Zeneca, Chugai, Eli Lilly, Janssen, Mitsubishi Tanabe, Nipponkayaku, Novartis, and Taiho. T. M. has received honoraria from Mitsubishi Tanabe, Astellas and Chugai; received research grants from Mitsubishi Tanabe, Astellas and Daiichi Sankyo. H. T. has received honoraria from Bristol-Myers Squibb. The other authors have no conflicts of interest. Publisher Copyright: {\textcopyright} 2018 Japan College of Rheumatology. Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = may,

day = "4",

doi = "10.1080/14397595.2018.1438093",

language = "English",

volume = "28",

pages = "383--408",

journal = "Modern rheumatology",

issn = "1439-7595",

publisher = "Springer Japan",

number = "3",

}

TY - JOUR

T1 - Clinical practice guideline for Sjögren’s syndrome 2017

AU - Sumida, Takayuki

AU - Azuma, Naoto

AU - Moriyama, Masafumi

AU - Takahashi, Hiroyuki

AU - Asashima, Hiromitsu

AU - Honda, Fumika

AU - Abe, Saori

AU - Ono, Yuko

AU - Hirota, Tomoya

AU - Hirata, Shintaro

AU - Tanaka, Yoshiya

AU - Shimizu, Toshimasa

AU - Nakamura, Hideki

AU - Kawakami, Atsushi

AU - Sano, Hajime

AU - Ogawa, Yoko

AU - Tsubota, Kazuo

AU - Ryo, Koufuchi

AU - Saito, Ichiro

AU - Tanaka, Akihiko

AU - Nakamura, Seiji

AU - Takamura, Etsuko

AU - Tanaka, Masao

AU - Suzuki, Katsuya

AU - Takeuchi, Tsutomu

AU - Yamakawa, Noriyuki

AU - Mimori, Tsuneyo

AU - Ohta, Akiko

AU - Nishiyama, Susumu

AU - Yoshihara, Toshio

AU - Suzuki, Yasunori

AU - Kawano, Mitsuhiro

AU - Tomiita, Minako

AU - Tsuboi, Hiroto

N1 - Funding Information: Therefore, standardization of diagnosis and treatment of SS is needed for appropriate management and accurate certification of designated intractable disease. CPG based on recently available evidences should also contribute to standardization of clinical practices across the country. The treatment guideline by the SS Foundation of the United States of America (USA) [2] and the management guideline for SS by the British Society for Rheumatology (BSR) [3] were published recently. Moreover, the CPG committee for SS, organized by the Research Team for Autoimmune Diseases, the Research Program for Intractable Disease of MHLW, has developed ‘CPG for SS 2017’ [4] which has been officially approved by both the Japan College of Rheumatology (JCR) and the Japanese society for SS (JSSS), according to the procedure proposed by the Medical Information Network Distribution Service (Minds) [5]. Funding Information: diseases are organized and supported by the Research Program for Intractable Disease of MHLW and the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED). The Research Program for Intractable Disease of MHLW provides support for epidemiological studies, establishes diagnostic and severity criteria, develops clinical practice guideline (CPG) based on clinical and therapeutic evidences, and distributes and revises these criteria and CPG. On the other hand, the Practical Research Project for Rare/ Intractable Diseases from AMED supports clinical research on gene therapy and clinical application of new therapies and medical devices, and provides financial support for physician-led clinical trials. Moreover, patients with designated intractable diseases can obtain medical expenses subsidy once they satisfy certain diagnostic and severity criteria. Funding Information: T. S. has received honoraria from Astellas, Chugai, and Mitsubishi Tanabe; research grants from Astellas, Bristol-Myers Squibb, Chugai, Mitsubishi Tanabe, and Ono. H. A. has received a research grant from Mitsubishi Tanabe. S. H. has received honoraria from AbbVie. Y. T. has received honoraria from AbbVie, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Teijin Pharma, Sanofi, Pfizer, Takeda, and Y. L. Biologics; research grants from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai., Eli Lilly, Kowa, Limited, Kyowa Hakko Kirin, Mitsubishi Tanabe, MSD, Novartis, Pfizer, Sanofi, Shionogi, Taisho Toyama, and Takeda. A. K. has received honoraria from AbbVie, Astellas, AstraZeneca, Bristol-Myers Squibb, Kissei, Mitsubishi Tanabe, Ono., Pfizer, and Takeda; research grants from Actelion, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Ono, and Takeda. H. S. has honorariums from Astellas, Bristol-Myers Squibb, Chugai, Mitsubishi Tanabe and Pfizer; research grants from Astellas and Chugai. K. T. has received research grants from Alcon, JINS, Santen, Fuji Xerox, Kowa, Ophtecs, Otsuka, QD Laser, Rohto, Sucampo Pharma, Pfizer, Tsubota Laboratory and Wakasa Seikatsu. M. T. has received research grants from AbbVie and Astellas; has belonged to the Donated Fund Laboratory sponsored by Mitsubishi Tanabe, Chugai, Bristol-Myers Squibb and Eisai. K. S. has received honoraria from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Fuji Film, Janssen, Kissei, Mitsubishi Tanabe, Pfizer, Shionogi and Takeda; research grants from Bristol-Myers Squibb, Daiichi Sankyo, Eisai and Kissei; consulting fees from AbbVie and Pfizer. T. T. has received honoraria from AbbVie, Astellas, Chugai, Daiichi Sankyo, Mitsubishi Tanabe and Pfizer; received research grants from AbbVie, Asahikasei Pharma, Astellas, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Nipponkayaku, Pfizer, Taisyo Toyama, Takeda, and Teijin Pharma; consulting fees from AbbVie, Astellas, Astra Zeneca, Chugai, Eli Lilly, Janssen, Mitsubishi Tanabe, Nipponkayaku, Novartis, and Taiho. T. M. has received honoraria from Mitsubishi Tanabe, Astellas and Chugai; received research grants from Mitsubishi Tanabe, Astellas and Daiichi Sankyo. H. T. has received honoraria from Bristol-Myers Squibb. The other authors have no conflicts of interest. Publisher Copyright: © 2018 Japan College of Rheumatology. Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2018/5/4

Y1 - 2018/5/4

N2 - Objectives: The objective of this study is to develop clinical practice guideline (CPG) for Sjögren’s syndrome (SS) based on recently available clinical and therapeutic evidences. Methods: The CPG committee for SS was organized by the Research Team for Autoimmune Diseases, Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Japan. The committee completed a systematic review of evidences for several clinical questions and developed CPG for SS 2017 according to the procedure proposed by the Medical Information Network Distribution Service (Minds). The recommendations and their strength were checked by the modified Delphi method. The CPG for SS 2017 has been officially approved by both Japan College of Rheumatology and the Japanese Society for SS. Results: The CPG committee set 38 clinical questions for clinical symptoms, signs, treatment, and management of SS in pediatric, adult and pregnant patients, using the PICO (P: patients, problem, population, I: interventions, C: comparisons, controls, comparators, O: outcomes) format. A summary of evidence, development of recommendation, recommendation, and strength for these 38 clinical questions are presented in the CPG. Conclusion: The CPG for SS 2017 should contribute to improvement and standardization of diagnosis and treatment of SS.

AB - Objectives: The objective of this study is to develop clinical practice guideline (CPG) for Sjögren’s syndrome (SS) based on recently available clinical and therapeutic evidences. Methods: The CPG committee for SS was organized by the Research Team for Autoimmune Diseases, Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW), Japan. The committee completed a systematic review of evidences for several clinical questions and developed CPG for SS 2017 according to the procedure proposed by the Medical Information Network Distribution Service (Minds). The recommendations and their strength were checked by the modified Delphi method. The CPG for SS 2017 has been officially approved by both Japan College of Rheumatology and the Japanese Society for SS. Results: The CPG committee set 38 clinical questions for clinical symptoms, signs, treatment, and management of SS in pediatric, adult and pregnant patients, using the PICO (P: patients, problem, population, I: interventions, C: comparisons, controls, comparators, O: outcomes) format. A summary of evidence, development of recommendation, recommendation, and strength for these 38 clinical questions are presented in the CPG. Conclusion: The CPG for SS 2017 should contribute to improvement and standardization of diagnosis and treatment of SS.

KW - Medical Information Network Distribution Service (Minds)

KW - Sjögren’s syndrome

KW - clinical practice guideline

KW - clinical question

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=85043701298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043701298&partnerID=8YFLogxK

U2 - 10.1080/14397595.2018.1438093

DO - 10.1080/14397595.2018.1438093

M3 - Review article

C2 - 29409370

AN - SCOPUS:85043701298

SN - 1439-7595

VL - 28

SP - 383

EP - 408

JO - Modern rheumatology

JF - Modern rheumatology

IS - 3

ER -

Clinical practice guideline for Sjögren’s syndrome 2017

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this